Polynucleotide (e.g., Nucleic Acid, Oligonucleotide, Etc.) Patents (Class 435/91.1)
  • Patent number: 11111500
    Abstract: Provided are compositions and methods relating to gene and/or protein mutations in transgenic or non-transgenic plants. In certain embodiments, the disclosure relates to mutations in the protoporphyrinogen IX (PPX) gene. In some embodiments the disclosure relates to plants that are herbicide resistant.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 7, 2021
    Assignees: CIBUS US LLC, CIBUS Europe B.V.
    Inventors: Gregory F. W. Gocal, Peter R. Beetham, Aura Estela Gonzalez Schopke, Sarah Dumm, James Pearce, Christian Schopke, Keith A. Walker
  • Patent number: 11104935
    Abstract: Kits for detecting analyte polynucleotides and an internal control in a sample. Included in the kit are an internal control polynucleotide and amplification reagents to co-amplify a first analyte polynucleotide and the internal control. Also included are first and second hybridization probes, each having a label indistinguishable from the other. The probes are respectively capable of hybridizing with a first analyte amplicon and an internal control amplicon. The first and second labels are indistinguishable homogeneous labels.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 31, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Sunghae A. Joo, Janel M. Dockter
  • Patent number: 11104943
    Abstract: The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples. The present disclosure provides methods for preparing cDNA and/or DNA molecules and cDNA and/or DNA libraries using modified reverse transcriptases.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 31, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Arkadiusz Bibillo, Pranav Patel
  • Patent number: 11085073
    Abstract: The present invention is directed to a method for immobilizing a nucleic acid molecule on a solid support and to a use of a combination of a first nucleic acid immobilized primer linked to a solid support and a second immobilized primer linked to said solid support in said method.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 10, 2021
    Assignee: QIAGEN GmbH
    Inventors: Christian Korfhage, Evelyn Fricke
  • Patent number: 10989724
    Abstract: Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 27, 2021
    Assignee: Labrador Diagnostics LLC
    Inventors: Elizabeth A. Holmes, Daniel Young, Samartha Anekal, Timothy Smith, James R. Wasson, Chinmay Pangarkar
  • Patent number: 10988501
    Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 27, 2021
    Inventors: Handong Li, Snezana Drmanac, Radoje Drmanac, Xun Xu, Lingling Peng, Scott Gablenz
  • Patent number: 10968451
    Abstract: Nucleic acid molecules such as shRNA clusters and artificial miRNA clusters are disclosed, Also disclosed are methods of use, compositions, cells, viral particles, and kits relating to the nucleic acid molecules disclosed herein. The disclosure provides, at least in part nucleic acid molecules such as shRNA clusters encoding shRNA-like molecules and artificial miRNA clusters encoding modified pri-miRNA-like molecules. The shRNA clusters and artificial miRNA clusters disclosed herein can be used, for example, to produce artificial RNA molecules, e.g., RNAi molecules. Cells, viral particles, compositions (e.g., pharmaceutical compositions), kits, and methods relating to the nucleic acid molecules, e.g., shRNA clusters and artificial miRNA clusters, are also disclosed. The nucleic acid molecules (e.g., shRNA clusters and artificial miRNA clusters), artificial RNA molecules (e.g., RNAi molecules), cells, viral particles, compositions (e.g.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 6, 2021
    Assignee: Texas Tech University System
    Inventors: Haoquan Wu, Jang-gi Choi
  • Patent number: 10953100
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 23, 2021
    Assignee: CENTUARI THERAPEUTICS LIMITED (GB/GB)
    Inventors: Christopher Pickford, Christine Watson, Melanie Glossop
  • Patent number: 10947545
    Abstract: The present invention relates to new aptamer molecules for use in therapy of a subject by inhibiting or suppressing the activation of TLR9 in a cell, a method of inhibiting or suppressing the activation of TLR9 in a cell using such aptamer molecules, a pharmaceutical composition and a kit comprising such aptamer molecules and the use of aptamer molecules for inhibiting or suppressing TLR9 activation.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 16, 2021
    Assignee: Berlin Cures GmbH
    Inventors: Annekathrin Haberland, Katrin Wenzel
  • Patent number: 10934569
    Abstract: This invention relates to processes that transcribe DNA molecules containing non-standard nucleotides using variants of T7 RNA polymerase to give RNA transcripts that contain their complementary non-standard nucleotides. Non-standard nucleotides pair during transcription using patterns of hydrogen bonding that are different from patterns that join the thymine-adenine and guanine-cytosine nucleobase pairs.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 2, 2021
    Inventors: Nicole A Leal, Steven A Benner
  • Patent number: 10934547
    Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 2, 2021
    Assignee: Northwestern University
    Inventors: Marcus E. Peter, Andrea E. Murmann
  • Patent number: 10927140
    Abstract: Methods for reverse automated nucleic acid synthesis, and 5?-H-phosphonates suitable for use in the same, as well as methods for making 5?-H-phosphonates, are described.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: February 23, 2021
    Assignee: The University of Toledo
    Inventors: Matthew Ellis, Amanda Bryant-Friedrich
  • Patent number: 10920226
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for LDHA.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 16, 2021
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 10881743
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: January 5, 2021
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Patent number: 10870872
    Abstract: The disclosure provides methods for making a polynucleotide wherein the addition of nucleotides can be physically, chemically and/or enzymatically controlled. The methods include combining a selected nucleotide, cations, an error prone or template independent DNA polymerase at a reaction site including an initiator sequence attached thereto and having a 3? terminal nucleotide, wherein the reaction reagents can be modulated and under conditions that allow covalent addition of one or more of a selected nucleotide to the 3? terminal nucleotide such that the selected nucleotide becomes a 3? terminal nucleotide, and repeating the addition step until the polynucleotide is formed.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: December 22, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Henry Hung-yi Lee, George M. Church, Reza Kalhor
  • Patent number: 10851138
    Abstract: Disclosed are methods related to the generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases, such as methods of preparing P. gingivalis antibodies, comprising immunizing a non-human animal with a chimeric or fusion protein, wherein the protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 1, 2020
    Assignee: ORAL HEALTH AUSTRALIA PTY LTD
    Inventors: Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J Cross, Nada Slakeski
  • Patent number: 10801058
    Abstract: Disclosed is a method of quality control of nucleic acid amplification using quality control oligonucleotide. The method comprises a nucleic acid detection step and a determination step. The nucleic acid detection step comprises the steps of: preparing a nucleic acid sample containing a target nucleic acid and a quality control polynucleotide; preparing a compartment containing one molecule of the target nucleic acid and a compartment containing one molecule of the quality control polynucleotide; and carrying out nucleic acid amplification of the target nucleic acid and the quality control polynucleotide, in the compartments, and carrying out signal detection using a detection probe to detect a signal originated from the detection probe. In the determination step, it is determined as to whether or not the nucleic acid detection step is proper on the basis of the result obtained in the signal detection step.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: October 13, 2020
    Assignee: SYSMEX CORPORATION
    Inventors: Tsuyoshi Nakano, Yuichiro Yoshida
  • Patent number: 10738306
    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3?UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 11, 2020
    Assignee: CureVac AG
    Inventor: Andreas Thess
  • Patent number: 10704084
    Abstract: The present disclosure is directed to methods and kits for identifying, enriching, and evaluating templated assembly reactants. Some embodiments disclose methods for identifying templated assembly targets by synthesizing templated assembly reactants, hybridizing the templated assembly reactants to target nucleic acids, performing a templated assembly reaction, and identifying the target nucleic acids that hybridized to the templated assembly reactants. Libraries of templated assembly reactants, a kit for identifying templated assembly targets, and a pair of templated assembly targets enriched from a library of chemically-ligated oligonucleotides spatially elicited (CLOSE) products are also disclosed.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 7, 2020
    Assignee: TriBiotica LLC
    Inventors: Ian Dunn, Matthew Lawler
  • Patent number: 10688174
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: June 23, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
  • Patent number: 10639609
    Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 5, 2020
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
  • Patent number: 10618024
    Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: April 14, 2020
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
  • Patent number: 10576446
    Abstract: Provided herein is a method for capturing DNA molecules in solution. The method may comprise: extracting DNA from a sample that comprises endogenous DNA and environmental DNA to produce extracted DNA; ligating universal adaptors to the extracted DNA; hybridizing the extracted DNA, in solution, with affinity-tagged RNA probes generated by: in vitro transcribing a library of fragmented reference genomic DNA that has been ligated to an RNA promoter adaptor, in the presence of an affinity-tagged ribonucleotide; binding the product with a capture agent that is tethered to a substrate in the presence of RNA oligonucleotides that are complementary to the adaptors, thereby capturing the hybridized DNA molecules on the substrate; washing the substrate to remove any unbound DNA molecules; and releasing the captured DNA molecules. A kit for performing the method is also provided.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: March 3, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Carlos D. Bustamante, Meredith L. Carpenter, Jason D. Buenrostro, William J. Greenleaf
  • Patent number: 10564118
    Abstract: Methods for detecting polynucleotides, especially the DNA replicated from samples obtained from subjects infected with pathogenic viruses such as human immunodeficiency virus, by detecting electromagnetic signals (“EMS”) emitted by such polynucleotides, and methods for improving the sensitivity of the polymerase chain reaction (“PCR”).
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 18, 2020
    Inventor: Luc Montagnier
  • Patent number: 10538795
    Abstract: The present invention relates to methods for generating a labelled nucleic acid from an RNA comprising a 5? protecting group, said method comprises the steps of obtaining a mixture of template strands of nucleic acids, said mixture comprising said RNA and further potentially other nucleic acids without a 5? protecting group, annealing at least one oligonucleotide primer to the template strand of said RNA and potentially other nucleic acids, and template sequence dependent extending said primer, thereby obtaining a complementary nucleic acid strand annealed to its template strand, or providing the RNA in duplex with a complementary nucleic acid strand annealed to its template strand, and optionally modifying the extension product of said nucleic acids without 5? protecting group either on the 5? end of the template strand or on the 3? end of the complementary strand, or both, and labelling a complementary nucleic acid of a double stranded nucleic acid not modified, wherein therefore the labelled nucleic acid d
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: January 21, 2020
    Assignee: LEXOGEN GMBH
    Inventors: Alexander Seitz, Irmlind Gabler, Lukas Paul
  • Patent number: 10538762
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 21, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David Corey, Jiaxin Hu
  • Patent number: 10519498
    Abstract: The invention relates to methods, compositions, devices, systems and kits are described including, without limitation, reagents and mixtures, for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: December 31, 2019
    Assignee: Qiagen Sciences, LLC
    Inventor: James J. DiMeo
  • Patent number: 10487353
    Abstract: Reaction mixture containing an analyte probe and an internal control probe, where the analyte probe and the internal control probe target different nucleic acids and have labels that generate signals that are indistinguishable from each other.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 26, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Sunghae A. Joo, Janel M. Dockter
  • Patent number: 10465184
    Abstract: The present invention relates to a method for preparing highly active silica magnetic nanoparticles, highly active silica magnetic nanoparticles prepared by the method, and a method of isolating nucleic acid using the highly active silica magnetic nanoparticles. The highly active silica magnetic nanoparticles prepared according to the present invention contain magnetic nanoparticles completely coated with silica, can be used as a reagent for isolating biomaterials, particularly, nucleic acids, and can isolate and purify nucleic acid in a high yield.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 5, 2019
    Assignee: BIONEER CORPORATION
    Inventors: Han Oh Park, Jae Ha Kim, Jong Gwang Park
  • Patent number: 10450595
    Abstract: Methods and compositions for the amplification of nucleic acids and generation of concatemers are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such as nucleic acid polymerases and primers.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: October 22, 2019
    Assignee: Theranos IP Company, LLC
    Inventors: Kamila Belhocine, Josephine Lee, Pranav Patel, Aaron Richardson, Scott Tabakman
  • Patent number: 10421990
    Abstract: A method and kits are provided for nucleic acid quantification and discrimination using surface plasmon resonance (SPR). The method provided is able to significantly enhance the detection limit and multiplex the discrimination assay using the melting properties of the target DNA on top of standard PCR reaction. By using the heating and cooling cycles of the polymerase chain reaction (PCR) or Ligation chain reaction (LCR), DNA is melted and hybridized onto the SPR sensor surface together with a nanoparticle label. Thus, during every cycle of DNA amplification, the quantity and type of target DNA can be monitored.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: September 24, 2019
    Assignee: FOX BIOSYSTEMS NV
    Inventors: Jeroen Lammertyn, Karel Knez, Filip Delport
  • Patent number: 10385393
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 20, 2019
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 10344282
    Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 9, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., COLD SPRING HARBOR LABORATORY
    Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
  • Patent number: 10323078
    Abstract: A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 18, 2019
    Assignees: Universite Paris Descartes, Assistance Publique—Hopitaux De Paris, Universite Paris—Sud, Universite Pierre et Marie Curie (Paris 6), Institut National De La Sante et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Institut Gustave-Roussy
    Inventors: Nicolas Dupin, Philippe Grange, Vincent Calvez, Joël Raingeaud
  • Patent number: 10308944
    Abstract: The present invention relates to polypeptide expression systems and methods of using the same.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 4, 2019
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Yonglei Shang
  • Patent number: 10307469
    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 4, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 10214573
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: February 26, 2019
    Assignees: Tivorsan Pharmaceuticals, Inc., Brown University
    Inventors: Justin Fallon, Elizabeth John
  • Patent number: 10202642
    Abstract: Provided herein is technology relating to sequencing nucleic acids and particularly, but not exclusively, to methods, compositions, systems, and kits for sequencing a nucleic acid using a degenerate two-base code. Particular embodiments provide: 1) that the two-base degenerate code relates a first element to a base comprising adenine (A) or guanine (G) and a second element to a base comprising cytosine (C) or thymine (T); 2) that the two-base degenerate code relates a first element to a base comprising A or C and a second element to a base comprising G or T; and 3) that the two-base degenerate code relates a first element to a base comprising G or C and a second element to a base comprising A or T.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: February 12, 2019
    Assignee: IBIS BIOSCIENCES, INC.
    Inventor: Mark W. Eshoo
  • Patent number: 10167508
    Abstract: The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: January 1, 2019
    Assignee: ARIOSA DIAGNOSTICS, INC.
    Inventors: Ken Song, Arnold Oliphant, John Stuelpnagel, Andrew Sparks
  • Patent number: 10087465
    Abstract: Compounds of the formula (Z)x wherein: each Z is independently selected from 2?-deoxythymidinyl moiety, 2?-deoxyadenosinyl moiety, and a 2?-deoxycytidinyl moiety, x is an integer from 5-20, wherein said 2?-deoxythymidinyl moieties are connected by thiophosphate triester linkages, and 3-12 of said thiophosphate triester linkages being positively charged linkages of the formula: where n is an integer from 2 to 6; and the remainder of the thiophosphate triester linkages are neutral linkages of the formula: provided that when x is 5-6, the number of positively charged linkages is 3, when x is 7-8, the number of positively charged linkages is 3-4, when x is 9-12, the number of positively charged linkages is 3-10, and when x is 13-20, the number of positively charged linkages is 4-12.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: October 2, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Serge L. Beaucage, Harsh V. Jain
  • Patent number: 10083341
    Abstract: Methods and systems for quantifying cellular activity using labeled probes, e.g., quantum dots, are disclosed. In one example approach, a method for quantifying cellular activity in a sample containing intact cells having labeled complexes comprises receiving images of the sample at a plurality of depths and detecting individual intact cells in the images of the sample at the plurality of depths. For each detected cell, discrete labels may be detected and localized in the cell at each depth, a total number of detected and localized labels may be calculated in the cell, and an activity level of the target molecule for the labeled probe in the cell determined.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 25, 2018
    Assignee: Oregon Health & Science University
    Inventors: Tania Vu, Thomas Jacob
  • Patent number: 10081837
    Abstract: In some embodiments, methods for obtaining sequence information from a nucleic acid template linked to a support include hybridizing a first primer to a template strand linked to a support, sequencing a portion of the nucleic acid template, thereby forming an extended first primer product that is complementary to a portion of the nucleic acid template, In some embodiments, the method further includes introducing a nick into a portion of the template strand that is hybridized to the extended first primer product, degrading a portion of the template strand from the nick using a degrading agent, where a portion of the extended first primer remains hybridized to an undegraded portion of the template strand, and sequencing at least some of the single-stranded portion of the extended first primer by synthesis.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: September 25, 2018
    Assignee: Life Technologies Corporation
    Inventors: Jason Myers, Zhoutao Chen, Devin Dressman, Theo Nikiforov
  • Patent number: 10041060
    Abstract: Methods are provided for constructing a synthetic genome, comprising generating and assembling nucleic acid cassettes comprising portions of the genome, wherein at least one of the nucleic acid cassettes is constructed from nucleic acid components that have been chemically synthesized, or from copies of the chemically synthesized nucleic acid components. In one embodiment, the entire synthetic genome is constructed from nucleic acid components that have been chemically synthesized, or from copies of the chemically synthesized nucleic acid components. Rational methods may be used to design the synthetic genome (e.g., to establish a minimal genome and/or to optimize the function of genes within a genome, such as by mutating or rearranging the order of the genes). Synthetic genomes of the invention may be introduced into vesicles (e.g., bacterial cells from which part or all of the resident genome has been removed, or synthetic vesicles) to generate synthetic cells.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: August 7, 2018
    Assignee: Synthetic Genomics, Inc.
    Inventors: J. Craig Venter, Hamilton O. Smith, Clyde A. Hutchison, III, Daniel G. Gibson
  • Patent number: 10030267
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 24, 2018
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 9950001
    Abstract: The disclosure provides methods and compositions for delivering polynucleotides into cells. The disclosure provides transiently protected polynucleotides comprising an anionic charge-neutralizing moiety/group, which may also confer additional functionality. These compounds can enter the cytosol of cells by endocytic or macropinocytic mechanisms. The transient protecting group is bioreversible, i.e., once inside a cell, it is designed to be removed by enzymatic activity or by passive intracellular methods (e.g., changes in pH or reductive environment).
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: April 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Steven F. Dowdy, Bryan R. Meade, Khirud Gogoi
  • Patent number: 9951386
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: April 24, 2018
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 9951333
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 24, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Charlotte Albaek Thrue, Majken Westergaard, Christoph Rosenbohm
  • Patent number: 9920305
    Abstract: Compositions and methods are provided for improved reverse transcriptases and their uses in reverse transcription where the improvement may include increased temperature, increased salt, increased activity and/or increased dUTP tolerance.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: March 20, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Yinhua Zhang, Thomas C. Evans, Jr.
  • Patent number: 9884885
    Abstract: This invention relates to novel method of synthesis of RNA utilizing N-2-acetyl protected guanine as nucleoside base, nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-acetyl protected guanine as nucleoside base protecting group, which is significantly faster base labile protecting group, yet significantly more stable than commonly utilized-2-isobutyryl guanosine is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups, including acetyl group from guanine and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: February 6, 2018
    Assignee: CHEMGENES CORPORATION
    Inventors: Suresh C. Srivastava, Naveen P. Srivastava
  • Patent number: 9862998
    Abstract: This disclosure provides a method of determining a sequence of nucleotides for a nucleic acid template. The method can include the steps of contacting the nucleic acid template with a conformationally labeled polymerase and at least four different nucleotide species under conditions wherein the conformationally labeled polymerase catalyzes sequential addition of the nucleotide species to form a nucleic acid complement of the nucleic acid template, wherein the sequential addition of each different nucleotide species produces a conformational signal change from the conformationally labeled polymerase and wherein the rate or time duration for the conformational signal change is distinguishable for each different nucleotide species; detecting a series of changes in the signal from the conformationally labeled polymerase under the conditions; and determining the rates or time durations for the changes in the signal, thereby determining the sequence of nucleotides for the nucleic acid template.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 9, 2018
    Assignee: ILLUMINA, INC.
    Inventors: Molly He, Cheng-Yao Chen, Eric Kool, Mostafa Ronaghi, Michael Previte, Rigo Pantoja